Leap Therapeutics Inc. (LPTX) stock prices were down by 2.67% as of the market closing on September 10th, 2021. This brought the price per share down to USD$1.46 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 28.08%, bringing it up to USD$1.87.
Success of Initial Data
September 13th, 2021 saw LPTX stock announce its plan to present initial data from its first-line cohort of the DisTinGuish study. The study is a Phase 2a clinical trial that is designed to evaluate the company’s anti-Dickkopf-1 (DKK1) antibody, DKN-01. The treatment will be administered in combination with tislelizumab, BeiGene’s anti-PD-1 antibody and chemotherapy. The study enrolled patients with gastric or gastroesophageal junction cancer (G/GEJ). The findings are expected to be presented at the European Society for Medical Oncology Congress, which will be held virtually from September 16th-21st 2021.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Scope of LPTX Stocks Trial
LPTX stock has been encouraged by the highly promising initial data from the DisTinGuish study. DKN-01 in combination with tislelizumab and chemotherapy has been shown to have high response rates in first-line patients with gastric and gastroesophageal junction cancer. Patients with tumors that exhibit high levels of DKK1 expression showed the highest response rates. High levels of DKK1 expression have been associated with aggressive disease progression and poor prognosis. The findings suggest the importance of the biomarker in predicting response to therapy.
Collaboration with Beigene
The study is being conducted in two parts, one in the United States and the other in the Republic of Korea. Enrollment of Part A has been concluded with 25 first-line HER2-G/GEJ cancer patients. The patients’ tumors exhibit either high levels of DKK1 (DKK1-high) or low levels (DKK1-low). Part B of the study is expected to enroll up to 48 patients with second-line, DKK1-high G/GEJ cancer. LPTX stock is conducting the ongoing combination study as part of an exclusive option and license agreement with BeiGene. The agreement is set to facilitate the development, commercialization, and proliferation of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Future Outlook for LPTX Stock
The company reported a promising quarter, consolidated by the positive outcome of the initial data from its DisTinGuish study. LPTX stock is keen to leverage the resources at its disposal to facilitate the speedy commercialization and proliferation of its proprietary treatment. Current and potential investors are hopeful that this will result in consistent and organic growth over the long term.
